Literature DB >> 979834

Spironolactone and acute mountain sickness.

T T Currie, P H Carter, W L Champion, G Fong, J K Francis, I H McDonald, R K Newing, I N Nunn, R N Sisson, M Sussex, R F Zacharin.   

Abstract

Thirteen adults trekking in Nepal in 1974 to altitudes between 4,300 m and 5,500 m remained free from acute mountain sickness while taking spironolactone as a prophylactic measure. Two years previously five of these adults trekking at similar altitudes, but without treatment, had suffered from acute mountain sickness. The regime used was spironolactone in a dosage of 25 mg three times a day for two days preceding and during the periods spent at altitudes above 3,000 m.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 979834

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  9 in total

1.  Comparative study of acetazolamide and spironolactone on body fluid compartments on induction to high altitude.

Authors:  M V Singh; S C Jain; S B Rawal; H M Divekar; R Parshad; A K Tyagi; K C Sinha
Journal:  Int J Biometeorol       Date:  1986-03       Impact factor: 3.787

2.  Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone.

Authors:  S C Jain; M V Singh; V M Sharma; S B Rawal; A K Tyagi
Journal:  Int J Biometeorol       Date:  1986-12       Impact factor: 3.787

Review 3.  Acetazolamide in acute mountain sickness.

Authors:  J G Dickinson
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-07

Review 4.  Medicine and mechanisms in altitude sickness. Recommendations.

Authors:  J H Coote
Journal:  Sports Med       Date:  1995-09       Impact factor: 11.136

5.  Acute mountain sickness.

Authors:  J S Milledge
Journal:  Thorax       Date:  1983-09       Impact factor: 9.139

6.  The effects of acetazolamide and spironolactone on the body water distribution of rabbits during acute exposure to simulated altitude.

Authors:  S C Jain; M V Singh; S B Rawal
Journal:  Int J Biometeorol       Date:  1984-05       Impact factor: 3.787

7.  Spironolactone prophylaxis in mountain sickness.

Authors:  L D Rutter
Journal:  Br Med J       Date:  1980-08-30

8.  Acute mountain sickness: pulmonary and cerebral oedema of high altitude.

Authors:  J S Milledge
Journal:  Intensive Care Med       Date:  1985       Impact factor: 17.440

Review 9.  Interventions for preventing high altitude illness: Part 2. Less commonly-used drugs.

Authors:  Alejandro Gonzalez Garay; Daniel Molano Franco; Víctor H Nieto Estrada; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2018-03-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.